Ascendis Pharma A/S, a biopharmaceutical leader dedicated to improving patients’ lives through its proprietary TransCon technology platform, recently announced a comprehensive update regarding its clinical programs for achondroplasia. On August 6, the company released significant 78-week data from its Phase 2 COACH trial, which evaluates a combination therapy of TransCon CNP (navepegritide) and TransCon hGH (lonapegsomatropin). The results suggest a potential paradigm shift in the treatment of achondroplasia, the most common form of disproportionate short stature. In addition to the clinical milestones, the company highlighted the rapid commercial uptake of YUVIWEL (navepegritide) in the United States, indicating strong market demand for differentiated therapeutic options in the pediatric endocrinology space.
The cornerstone of the recent announcement is the sustained efficacy and safety profile of the combination therapy. According to the company, children treated with the once-weekly combination of TransCon CNP and TransCon hGH achieved a mean annualized growth velocity (AGV) that met or exceeded the 97th percentile for children of average stature. This milestone is particularly noteworthy because it suggests that pharmacological intervention can not only improve growth but potentially align the growth trajectory of children with achondroplasia with that of their average-stature peers.
The Pathophysiology of Achondroplasia and the TransCon Approach
Achondroplasia is caused by a gain-of-function mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. This mutation leads to the overactivity of the FGFR3 protein, which negatively regulates bone growth by inhibiting the proliferation and differentiation of chondrocytes in the growth plate. The clinical manifestations extend beyond short stature, often including macrocephaly, spinal stenosis, obstructive sleep apnea, and significant limb bowing.
Ascendis Pharma’s approach utilizes its TransCon (Transient Conjugation) technology, which is designed to provide a sustained release of therapeutic proteins in their active, unmodified form. TransCon CNP is a long-acting prodrug of C-type Natriuretic Peptide (CNP). CNP is a natural regulator of bone growth that works by inhibiting the downstream signaling of the overactive FGFR3 receptor. By providing a once-weekly administration of CNP, Ascendis aims to maintain therapeutic levels of the peptide, thereby promoting more consistent bone growth.
The combination therapy adds TransCon hGH, a long-acting growth hormone already approved for other indications. The synergy between CNP—which targets the specific genetic pathway of achondroplasia—and growth hormone—which provides a generalized stimulus for linear growth—appears to offer a more robust response than monotherapy alone.
Detailed Analysis of the Phase 2 COACH Trial Results
The COACH trial is an ongoing, prospective, Phase 2 open-label study designed to investigate the efficacy, safety, and tolerability of the combination regimen. The trial enrolled children with achondroplasia aged 2 to 11 years, divided into two distinct cohorts to assess the impact of the therapy on different patient backgrounds.
The first cohort consisted of 12 TransCon CNP treatment-naïve children with a mean age of 5.26 years. The second cohort included nine children who had previously been treated with TransCon CNP monotherapy for an average of 2.56 years, with a mean age of 8.32 years. Both groups received a combination of once-weekly TransCon CNP at a dose of 100 µg/kg and once-weekly TransCon hGH starting at 0.30 mg/kg.
By Week 78, the data demonstrated that the growth velocity remained durable. Achieving an AGV in the 97th percentile of average-stature children represents a significant clinical benchmark. Traditionally, treatments for achondroplasia have aimed to close the gap between the growth rates of affected children and those without the mutation; however, reaching the upper percentiles of the general population suggests a high level of potency for the combination therapy.
Crucially, this accelerated growth did not come at the expense of patient safety. The trial reported that the safety and tolerability profile at Week 78 was consistent with earlier findings, with no new safety signals emerging from the combination of the two drugs. This is vital in pediatric populations, where long-term safety and the avoidance of adverse skeletal maturation (such as premature bone age advancement) are paramount.
Commercial Momentum and Patient-Centered Development
The commercial update regarding YUVIWEL in the United States reflects a growing confidence among healthcare providers and families in the TransCon platform. Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma, emphasized that the rapid uptake of the therapy reflects its "highly differentiated profile."
The pharmaceutical landscape for achondroplasia has evolved rapidly in recent years. Until recently, there were few options beyond surgical limb lengthening. The introduction of pharmacological agents has changed the conversation from purely managing complications to proactive growth modulation. Ascendis’s focus on once-weekly administration is a key differentiator, as it reduces the treatment burden on families compared to daily injection regimens.
Advocacy groups have also noted the importance of these developments. Chandler Crews, founder of The Chandler Project, noted that parents are increasingly seeking information on emerging drug programs to prevent the long-term complications of the condition. These complications, which include chronic pain and mobility issues, often lead to multiple surgeries throughout childhood and adolescence. The hope is that by improving skeletal development early in life, the need for these invasive interventions can be mitigated.
Broader Clinical Implications: Beyond Linear Growth
While height is the most easily measured metric in achondroplasia trials, the medical community is increasingly focusing on proportionality and functional outcomes. The ApproaCH trial, which focuses on TransCon CNP monotherapy, has provided insights into these secondary but critical benefits.
Data from completed and ongoing trials of TransCon CNP monotherapy have shown improvements in lower-limb alignment. Bowing of the legs (genu varum) is a common and debilitating feature of achondroplasia that often requires surgical correction. The ability of a pharmacological agent to improve alignment suggests that the therapy is influencing the quality and geometry of bone growth, not just the quantity.
Carlos Bacino, MD, a professor at Baylor College of Medicine, highlighted the importance of these long-term efficacy and safety data. He pointed out that the statistically significant improvements in height and lower-limb alignment, combined with a low rate of injection site reactions, position TransCon CNP as a potentially transformative treatment option.
However, the advocacy community remains cautious and analytical. Mike Hughes, Chair of the Biotech Industry Liaison Committee for Little People of America, noted that while anatomical changes are encouraging, it is essential to determine if these changes translate into meaningful differences in function and mobility. The goal for many in the community is to ensure that treatment decisions are based on balanced evidence that aligns with the individual goals and values of the families.
Chronology of Development and Future Outlook
The journey of TransCon CNP began with early-stage molecular design aimed at overcoming the short half-life of natural CNP. Following successful preclinical trials, the program moved into Phase 1 and Phase 2 studies (the ACCOMPLISH and ApproaCH trials), which established the safety and dose-response relationship of the monotherapy.
The introduction of the COACH trial represented a strategic expansion, testing the hypothesis that dual-pathway stimulation (CNP and GH) could yield superior results. The 78-week data released in August 2024 serves as a pivotal bridge to potential Phase 3 trials and subsequent regulatory filings.
Looking ahead, Ascendis Pharma is expected to continue its data collection to support global regulatory submissions. The company’s strategy involves not only securing approvals for monotherapy but also establishing the combination therapy as a gold standard for patients who may require more intensive growth support.
The success of the achondroplasia program also reinforces the validity of the TransCon technology across other therapeutic areas. Ascendis has already seen success with SKYTROFA (lonapegsomatropin) for growth hormone deficiency, and the positive momentum in achondroplasia further solidifies its position in the endocrinology market.
Conclusion and Market Impact
The Week 78 results from the COACH trial represent a milestone for Ascendis Pharma and the achondroplasia community. By demonstrating that a combination of TransCon CNP and TransCon hGH can achieve growth velocities comparable to the highest percentiles of average-stature children, the company has set a new benchmark for efficacy.
As YUVIWEL continues its rollout in the United States, the focus will likely shift toward long-term real-world evidence. The medical community will be watching closely to see if the improvements in height and limb alignment lead to a reduction in the "medical burden" of achondroplasia—specifically, whether these children will experience fewer surgeries and a higher quality of life as they reach adulthood.
For investors and industry analysts, the steady progress of the achondroplasia pipeline suggests that Ascendis is successfully navigating the transition from a research-focused biotech to a commercial-stage pharmaceutical powerhouse. With a commitment to patient-centered development and a robust technological foundation, the company appears well-positioned to remain at the forefront of pediatric endocrinology for the foreseeable future.
